Progress in Clinical Development of Efgartigimod for Primary Sjogren’s Disease by Argenx
A global immunology company dedicated to enhancing the lives of individuals grappling with severe autoimmune conditions has unveiled its intention to propel the development of efgartigimod into Phase 3 for…
CVS Health® Allocates Over $3 Million to Organizations Enhancing Health Outcomes in Phoenix
The CVS Health® (NYSE: CVS) today announced more than $3 million in new grants to support organizations in Phoenix working to increase equitable access to health care, address social determinants of…
Bristol Myers Squibb Confirms Success of KRAZATI Trial in KRAS G12C-Mutated Lung Cancer
Bristol Myers Squibb (NYSE: BMY) has announced the successful results of the pivotal Phase 3 KRYSTAL-12 study, which evaluated KRAZATI® (adagrasib) as a monotherapy for patients with previously treated locally…
Bristol Myers Squibb Updates Phase 3 YELLOWSTONE Trial Progress: Oral Zeposia (Ozanimod) Evaluation in Moderate to Severe Active Crohn’s Disease Patients
Bristol Myers Squibb (NYSE: BMY) provided an update today following the preliminary analysis of findings from the first of two induction studies within the Phase 3 YELLOWSTONE clinical trial program,…
Bristol Myers Squibb Broadens Health Equity Grant Programs for Enhanced Health Results
Bristol Myers Squibb (NYSE: BMY) has introduced a $1.8 million initiative aimed at promoting health equity by tackling social determinants of health (SDoH) in four countries with underserved patient populations:…
Bristol Myers Squibb Presents New Cardiovascular Findings at 2024 ACC Conference, Strengthening Evidence Base
Bristol Myers Squibb (NYSE: BMY) announced today the unveiling of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, scheduled for April 6-8, 2024, in Atlanta,…
FDA Approves Roche’s Groundbreaking Molecular Test for Malaria Screening in Blood Donors
Roche, a leading healthcare company (SIX: RO, ROG; OTCQX: RHHBY), has announced today the approval by the U.S. Food and Drug Administration (FDA) for its cobas® Malaria test, designed for…
EU Greenlights Merck’s KEYTRUDA® Combo for High-Risk NSCLC Treatment
Merck, also known as MSD outside of the United States and Canada, has announced today that the European Commission (EC) has granted approval for KEYTRUDA, Merck’s anti-PD-1 therapy. This approval…
Breakthrough FDA Approval: Merck’s WINREVAIR™ Revolutionizes PAH Treatment for Adults
Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk, branded as WINREVAIR™ in…
AbbVie’s Acquisition of Landos Biopharma Bolsters its Reach in Inflammatory and Autoimmune Conditions
AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) have announced a definitive agreement today, wherein AbbVie will acquire Landos, a clinical stage biopharmaceutical company primarily focused…
Novo Nordisk’s Acquisition of Cardior Pharmaceuticals: Enhancing Cardiovascular Disease Pipeline
Novo Nordisk and Cardior Pharmaceuticals have announced a significant acquisition deal, with Novo Nordisk set to acquire Cardior for up to 1.025 billion Euros. This includes an upfront payment along…
Awiqli®: European Authorities Recommend Approval for Weekly Basal Insulin Icodec in Diabetes Treatment
Novo Nordisk has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion, recommending the marketing authorization for Awiqli® (the branded…